dc.contributor.author | Romero Sanz, Silvia | |
dc.contributor.author | Caldero Escudero, Elena | |
dc.contributor.author | Álvarez Illera, María Pilar | |
dc.contributor.author | Santo Domingo Mayoral, Jaime | |
dc.contributor.author | Fonteriz García, Rosalba Inés | |
dc.contributor.author | Montero Zoccola, María Teresa | |
dc.contributor.author | Álvarez Martín, Javier | |
dc.date.accessioned | 2024-02-09T11:30:20Z | |
dc.date.available | 2024-02-09T11:30:20Z | |
dc.date.issued | 2023 | |
dc.identifier.citation | Frontiers in Pharmacology, 2023, vol. 14, 1182428 | es |
dc.identifier.issn | 1663-9812 | es |
dc.identifier.uri | https://uvadoc.uva.es/handle/10324/66076 | |
dc.description | Producción Científica | es |
dc.description.abstract | Introduction: The high prevalence of neurodegenerative diseases in our
population and the lack of effective treatments encourage the search for new
therapeutic targets for these pathologies. We have recently described that
submaximal inhibition of the Sarco-Endoplasmic Reticulum Ca2+ ATPase
(SERCA), the main responsible for ER calcium storage, is able to increase
lifespan in Caenorhabditis elegans worms by mechanisms involving
mitochondrial metabolism and nutrient-sensitive pathways.
Methods: We have studied here the effects of submaximal SERCA inhibition in a
chemicalmodel of Parkinson’s disease (PD) induced in C. elegansworms by treatment
with themitochondrial complex I inhibitor rotenone. For specific SERCA inhibition,we
treated worms with RNAi against sca-1, the sole orthologue of SERCA in C. elegans.
Results and Discussion: Our results show that rotenone produces alterations in
worms that include decreased lifespan, smaller size, reduced fertility, decreased
motility, defecation and pumping rate, increased mitochondrial ROS production,
reduced mitochondrial membrane potential and oxygen consumption rate, altered
mitochondrial structure, and altered ethanol preference in behavioral studies. Most of
these alterations were either fully or partially reversed in worms treated with sca-1
RNAi, suggesting that SERCA inhibition could be a novel pharmacological target in the
prevention or treatment of neurodegeneration. | es |
dc.format.mimetype | application/pdf | es |
dc.language.iso | eng | es |
dc.publisher | Frontiers | es |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | * |
dc.subject.classification | C. elegans | es |
dc.subject.classification | rotenone | |
dc.subject.classification | Parkinson’s disease | |
dc.subject.classification | SERCA | |
dc.subject.classification | lifespan | |
dc.subject.classification | endoplasmic reticulum | |
dc.subject.classification | mitochondria | |
dc.subject.classification | Ca2+ signaling | |
dc.title | SERCA inhibition improves lifespan and healthspan in a chemical model of Parkinson disease in Caenorhabditis elegans | es |
dc.type | info:eu-repo/semantics/article | es |
dc.rights.holder | © 2023 The Authors | |
dc.identifier.doi | 10.3389/fphar.2023.1182428 | es |
dc.relation.publisherversion | https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1182428/full | es |
dc.identifier.publicationtitle | Frontiers in Pharmacology | es |
dc.identifier.publicationvolume | 14 | es |
dc.peerreviewed | SI | es |
dc.description.project | MICINN BFU 2017-83509-R | es |
dc.description.project | MICINN PID 2021-122239OB-I00 | es |
dc.identifier.essn | 1663-9812 | es |
dc.rights | Attribution 4.0 Internacional | * |
dc.type.hasVersion | info:eu-repo/semantics/publishedVersion | es |
dc.subject.unesco | 2411.99 Otras | es |
dc.subject.unesco | 3209.99 Otras | es |